Last reviewed · How we verify
Cabazitaxel + Androgen deprivation therapy
Cabazitaxel + Androgen deprivation therapy is a Taxane chemotherapy + Androgen deprivation therapy Small molecule drug developed by Örebro University, Sweden. It is currently in Phase 3 development for Metastatic castration-resistant prostate cancer (mCRPC). Also known as: Jevtana-Leuporelin.
Cabazitaxel is a microtubule-stabilizing chemotherapy combined with androgen deprivation therapy to suppress testosterone production, targeting castration-resistant prostate cancer through dual mechanisms.
Cabazitaxel is a microtubule-stabilizing chemotherapy combined with androgen deprivation therapy to suppress testosterone production, targeting castration-resistant prostate cancer through dual mechanisms. Used for Metastatic castration-resistant prostate cancer (mCRPC).
At a glance
| Generic name | Cabazitaxel + Androgen deprivation therapy |
|---|---|
| Also known as | Jevtana-Leuporelin |
| Sponsor | Örebro University, Sweden |
| Drug class | Taxane chemotherapy + Androgen deprivation therapy |
| Target | Microtubules (cabazitaxel); androgen receptor pathway (ADT) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cabazitaxel is a taxane that binds to and stabilizes microtubules, disrupting cell division and inducing apoptosis in rapidly dividing cancer cells. When combined with androgen deprivation therapy (ADT), which blocks testosterone production or signaling, the regimen addresses both hormone-sensitive and hormone-resistant prostate cancer cells, improving overall survival in metastatic castration-resistant prostate cancer (mCRPC).
Approved indications
- Metastatic castration-resistant prostate cancer (mCRPC)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Diarrhea
- Nausea
- Fatigue
- Peripheral neuropathy
Key clinical trials
- Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel (PHASE2)
- A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse (PHASE3)
- Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer (PHASE1)
- Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer (PHASE3)
- Efficacy Study Evaluating Chemotherapy in Prostate Cancer (PHASE3)
- Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cabazitaxel + Androgen deprivation therapy CI brief — competitive landscape report
- Cabazitaxel + Androgen deprivation therapy updates RSS · CI watch RSS
- Örebro University, Sweden portfolio CI
Frequently asked questions about Cabazitaxel + Androgen deprivation therapy
What is Cabazitaxel + Androgen deprivation therapy?
How does Cabazitaxel + Androgen deprivation therapy work?
What is Cabazitaxel + Androgen deprivation therapy used for?
Who makes Cabazitaxel + Androgen deprivation therapy?
Is Cabazitaxel + Androgen deprivation therapy also known as anything else?
What drug class is Cabazitaxel + Androgen deprivation therapy in?
What development phase is Cabazitaxel + Androgen deprivation therapy in?
What are the side effects of Cabazitaxel + Androgen deprivation therapy?
What does Cabazitaxel + Androgen deprivation therapy target?
Related
- Drug class: All Taxane chemotherapy + Androgen deprivation therapy drugs
- Target: All drugs targeting Microtubules (cabazitaxel); androgen receptor pathway (ADT)
- Manufacturer: Örebro University, Sweden — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic castration-resistant prostate cancer (mCRPC)
- Also known as: Jevtana-Leuporelin
- Compare: Cabazitaxel + Androgen deprivation therapy vs similar drugs
- Pricing: Cabazitaxel + Androgen deprivation therapy cost, discount & access